Chartsonlygoup's future update (it'll live): tomwong.xyz/stock-status/

What is ALXN's Net Revenue (Sales)?

  Alexion Pharmaceuticals Inc ( ALXN ) |
1995 - 2021 (27 years)

Net Revenue (Sales) is 
$6.2B (1Y +11.9% )

ALXN Stock Price & Net Revenue (Sales)

Net Revenue (Sales) for ALXN competitors.
CELG GILD REGN VRTX BIIB AGIO RARE IONS QGEN XON
Note: Stonk = Stock. Both words are used interchangeably. 🙂

Historical (All-Time) Stats for Net Revenue (Sales)

chevron_right 2021 $1.6B +3182x
( +34.8% / year avg)
chevron_left 1995 $500.0K
vertical_align_top Peak $5.9B +11723x
vertical_align_bottom Bottom $500.0K
arrow_drop_up # Up Years 19 19 of 27
years up.
arrow_drop_down # Down Years 8
Up Years = Positive (0%+) YoY change
Down Years = Zero or Negative (0% or less) YoY change

Key Points (Stonk Price Comparison)

  • ALXN's stock price has rallied +4,601% from $2.31 in 1995 , or +0.01x the rate relative to it's net revenue (sales) over the same period.
  • If ALXN grows it's stock at the same rate as it's net revenue (sales) (+34.8%/year) , it's stock price will grow +1,981% and hit $2153.81 over the next 10 years.
  • ALXN's stock price has gone up 0 of the 19 years (0%) it's net revenue (sales) were also up.
  • ALXN Historical Net Revenue (Sales) Table
    in $ million
    Year Net Revenue (Sales) YoY % Change Stock Price YoY % Change (Stock Price)
    4/1/2021 $1,591 -72.8% - -
    4/1/2020 $5,862 23.8% - -
    4/1/2019 $4,735 21.0% - -
    4/1/2018 $3,912 12.7% - -
    4/1/2017 $3,471 61.1% - -
    4/1/2016 $2,155 -13.9% - -
    4/1/2015 $2,502 20.5% - -
    4/1/2014 $2,076 45.2% - -
    4/1/2013 $1,429 37.3% - -
    4/1/2012 $1,041 46.3% - -
    4/1/2011 $711 43.6% - -
    4/1/2010 $495 40.2% - -
    4/1/2009 $353 64.0% - -
    4/1/2008 $215 461.8% - -
    4/1/2007 $38 2337.8% - -
    4/1/2006 $1 6.4% - -
    4/1/2005 $1 -67.9% - -
    4/1/2004 $4 534.8% - -
    4/1/2003 $0 -85.5% - -
    4/1/2002 $4 -50.6% - -
    4/1/2001 $10 -45.1% - -
    4/1/2000 $18 -26.0% - -
    4/1/1999 $24 1506.5% - -
    4/1/1998 $1 -77.9% - -
    4/1/1997 $7 133.3% - -
    4/1/1996 $3 500.0% - -
    4/1/1995 $0 - - -

  • About
    Industry: Biotechnology
    Sector: Healthcare
    Country: US
    IPO Date: 2/1/1996
    Stonk Exchange: NASDAQ
    • Alexion Pharmaceuticals, Inc
    • is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.
    • The company is headquartered in Boston, Massachusetts and currently employs 2,656 full-time employees.
    • The firm is focused on the development and commercialization of therapeutic products.
    • The firm's products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).
    • The firm's clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
    • Its Soliris is the therapeutic approved for patients with either paroxysmal nocturnal hemoglobinuria (PNH) or hemolytic uremic syndrome (aHUS).
    • PNH and aHUS result from chronic uncontrolled activation of the complement component of the immune system.
    • Its Strensiq is for the treatment of patients with Hypophosphatasia (HPP).
    • Its product, Kanuma is for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D).
    • The company is a recombinant form of the human LAL enzyme, which is a replacement therapy that is approved for the treatment for patients with LAL-D.

  • "The Top Line"

    The revenue (or sales) is the value of a company's sales of goods and services to its customers. Although a company's bottom line (its net income) gets most of the attention from investors, the top line is where the revenue or income process begins. Also, in the long run, profit margins on a company's existing products tend to eventually reach a maximum that is difficult to improve. Thus, companies typically can grow no faster than their revenues.

    For more detailed definitions, please see Investopedia.